Abstract
Aim of the Study. To verify the effect of modified sini decoction on patients with hepatitis B virus related acute-on-chronic liver failure. Materials and Methods. A retrospective cohort study was conducted. Patients who had been treated with modified sini decoction and standard comprehensive internal medicine were assigned to an observation group, and patients who had been treated with standard comprehensive internal medicine were selected as a control group. The total bilirubin (TBIL), albumin (ALB), alanine aminotransferase (ALT), prothrombin activity (PTA), CTP, and MELD scores were analyzed at weeks 4, 8, and 12 after treatment, respectively. Meanwhile, the 12-week survival rate was analyzed. Results. The levels of TBIL and ALT were remarkably decreased, while the levels of ALB and PTA were remarkably increased in both groups at weeks 4, 8, and 12 after treatment, respectively, but the effects in the observation group were greater (P < 0.05). The CTP and MELD scores at 8-week and 12-week were lower in the observation group than in the control group (P < 0.05). At 12 weeks, the mean survival times of the observation group and the control group were 66.7 and 45.5 d, respectively. Significant improvement of 12-week survival rate [39/62 (62.9%) versus 18/50 (36.0%), P = 0.001] was observed in the observation group after treatment. Conclusions. Modified sini decoction could protect the liver function and improve the survival rates of patients with hepatitis B virus related acute-on-chronic liver failure.
Highlights
Liver failure has various clinical types, a complex pathogenesis, and rapid disease progression, as well as a high mortality rate [1]
In most Asian countries, the aetiology of Acute-on-chronic liver failure (ACLF) is primarily due to hepatitis B virus (HBV) infection because of the high prevalence of it [3]
One hundred and twelve patients were enrolled from 184 cases with hepatitis B virus related acute-onchronic liver failure from Hospital of Chengdu University of Traditional Chinese Medicine
Summary
Liver failure has various clinical types, a complex pathogenesis, and rapid disease progression, as well as a high mortality rate [1]. ACLF is characterized by an acute deterioration with preexisting chronic liver diseases and results in increased mortality due to multisystem organ failure [2]. Hepatitis B virus related acute-on-chronic liver failure (HBVACLF) caused by HBV infection is the most common type in China with various complications and a mortality rate as high as 40%-90% [1, 6, 7]. Liver transplantation is the most effective treatment, which can increase the survival rates of patients with liver failure [5]. It is severely limited by high costs and donor shortage [8, 9]. It is time to explore a new strategy to cure HBV-ACLF
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
